NIMUSTINE HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H13ClN6O2.ClH
Molecular Weight	309.152
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

Cl.CC1=NC(N)=C(CNC(=O)N(CCCl)N=O)C=N1

InChI

InChIKey=KPMKNHGAPDCYLP-UHFFFAOYSA-N

InChI=1S/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H

HIDE SMILES / InChI

Description

Nimustine is one of nitrosoureas used in the treatment of cancer. Nimustine alkylates and crosslinks DNA, thereby causing DNA fragmentation, inhibition of protein synthesis, and cell death. It is used in the treatment of brain tumor (in particular, high-grade gliomas), gastrointestinal cancers (stomach cancer, liver cancer, colorectal cancer), lung cancer, malignant lymphoma, chronic leukemia. Nimustine side effects are: leukopenia, thrombocytopenia, hypoproteinemia, anemia, Increased bleeding, proteinuria, interstitial pneumonia, anorexia, stomatitis, nausea, vomiting, general weakness, fever, headache, dizziness, seizures, alopecia, allergic reactions (rash).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA	Crosslinking Agent

Conditions

Condition	Modality	Highest Phase	Product
Brain cancer	Primary	Approved	NIDRAN
Gastrointestinal cancer	Primary	Approved	NIDRAN
Lung cancer	Primary	Approved	NIDRAN
Malignant lymphoma	Primary	Approved	NIDRAN
Chronic leukemia	Primary	Approved	NIDRAN

C_max

Value	Dose	Co-administered	Analyte	Population
0.59 μg/mL	100 mg single, intravenous		NIMUSTINE cerebrospinal fluid	Homo sapiens
3.86 μg/mL	100 mg single, intravenous		NIMUSTINE blood	Homo sapiens
1.08 μg/mL	5 mg single, intraventricular	CYTARABINE	NIMUSTINE cerebrospinal fluid	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
2.21 μg × h/mL	100 mg single, intravenous		NIMUSTINE blood	Homo sapiens
1.08 μg × h/mL	5 mg single, intraventricular	CYTARABINE	NIMUSTINE cerebrospinal fluid	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.49 h	100 mg single, intravenous		NIMUSTINE cerebrospinal fluid	Homo sapiens
0.58 h	100 mg single, intravenous		NIMUSTINE blood	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
35.1%			NIMUSTINE serum	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
90 mg/m2 1 times / 5 weeks multiple, intraarterial Highest studied dose	unhealthy, ADULT
90 mg/m2 1 times / 5 weeks multiple, intravenous Highest studied dose	unhealthy, ADULT
40 mg/m2 1 times / 4 weeks multiple, intravenous MTD	unhealthy, ADULT	DLT: Neutropenia...
45 mg/m2 1 times / 4 weeks multiple, intravenous Studied dose	unhealthy, ADULT	DLT: Thrombocytopenia, Neutropenia...
75 mg/m2 1 times / 6 weeks multiple, intravenous Studied dose	unhealthy, ADULT	Disc. AE: Myelosuppression...

Showing 1 to 5 of 5 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Neutropenia	grade 3, 16.7% DLT	40 mg/m2 1 times / 4 weeks multiple, intravenous MTD	unhealthy, ADULT
Thrombocytopenia	grade 3, 33.3% DLT	45 mg/m2 1 times / 4 weeks multiple, intravenous Studied dose	unhealthy, ADULT
Neutropenia	grade 3, 66.7% DLT	45 mg/m2 1 times / 4 weeks multiple, intravenous Studied dose	unhealthy, ADULT
Myelosuppression	4.2% Disc. AE	75 mg/m2 1 times / 6 weeks multiple, intravenous Studied dose	unhealthy, ADULT

Showing 1 to 4 of 4 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Efficacy of single-bolus vs. frequent low-dose treatment with nitrosourea in experimental gliomas.	2001 May-Jun	11497267
Randomized controlled trial on malignant brain tumors--activities of the Japan Clinical Oncology Group-Brain Tumor Study Group.	2004 Apr	15185766
Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas.	2004 Dec	15662974
Treatment of low-grade oligodendroglial tumors without radiotherapy.	2004 Dec 28	15623706
[Study on MGMT assay and tumor individual predictable chemotherapy].	2004 Jun	15191682

Showing 1 to 5 of 29 entries

Previous1 2 3 4 5 6Next

Patents

Sample Use Guides

In Vivo Use Guide

2-3 mg/kg or 90-100 mg/m2 as a single dose at intervals of 6 wk according to haematological response.

Route of Administration: Other

In Vitro Use Guide

After 24h treated of drug, ACNU induced cytotoxicity in NIH/3T3 cells with the IC50 about 600 ug/ml. At lower ACNU concentrations (<100 ug/ml), less growth inhibition was observed, but it can produce markedly increased cytotoxicity between the concentration of 100~900 ug/ml.

Show entries

Name

Type

Language

NIMUSTINE HYDROCHLORIDE

Common Name

English

NIMUSTINE HCL

Common Name

English

NIDRAN

Brand Name

English

NIMUSTINE HYDROCHLORIDE [JAN]

Common Name

English

NSC-245382

Code

English

Showing 1 to 5 of 10 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Antineoplastic Alkylating Agent

NCI_THESAURUS

C699

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

CHEBI

7576

PRIMARY

NSC

245382

PRIMARY

EPA CompTox

DTXSID80204185

PRIMARY

PUBCHEM

91657

PRIMARY

CAS

52208-23-8

SUPERSEDED

Showing 1 to 5 of 13 entries

Previous1 2 3Next

ACTIVE MOIETY


					0S726V972K

NIMUSTINE

SUBSTANCE RECORD


					DFR965WKBU

NIMUSTINE HYDROCHLORIDE

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound